top of page
Full-bleed Progress.jpg

Pipeline

We are advancing

a robust pipeline

of Supercharged Cell therapies

POWERED BY OUR PROPRIETARY CELL ENHANCEMENTS

Product
Modality
Indications
Discovery
Lead Optimization
PCC
IIT
IND/PH1
CIB-301
LVV
RCC, CRC, NSCLC,
etc.
CIB-350
LVV
B-ALL and auto immunity
CIB-310
LVV
CRC, solid tumors
CIB-380
LVV
MM and auto immunity
CIB-500s
LVV
solid tumors
CIB-600s
LVV
solid tumors

Program stages reflect the latest portfolio overview provided by Cellinfinity.

CLINICAL DEVELOPMENT

Advancing In Vivo CAR-T Cell Therapy into Clinical Evaluation

Cellinfinity Bio is advancing its next-generation in vivo CAR-T cell therapy platform toward clinical evaluation, with a Phase 1 clinical trial registered on ClinicalTrials.gov.

​

The study, titled “CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors,” is designed to evaluate the investigational therapy in patients with advanced malignancies. This open-label, dose-escalation study represents an important step in the clinical development of in vivo CAR-T cell therapy.

REGISTERED CLINICAL TRIAL

Phase 1(IIT)

Open-label,
dose-escalation

NCT07657585

Clinical Trial Information
CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors

IDENTIFIER

NCT07657585

STUDY PHASE

Phase 1 (IIT)

STUDY DESIGN

Open-label, dose-escalation

STUDY LOCATION

Beijing, China

STUDY SPONSOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

COLLABORATOR

Cliniboosta Biotech

COLLABORATION

Cellinfinity has multiple pre-clinical candidates available for collaborations.
bottom of page